AU2017310163B2 - Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same - Google Patents

Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same Download PDF

Info

Publication number
AU2017310163B2
AU2017310163B2 AU2017310163A AU2017310163A AU2017310163B2 AU 2017310163 B2 AU2017310163 B2 AU 2017310163B2 AU 2017310163 A AU2017310163 A AU 2017310163A AU 2017310163 A AU2017310163 A AU 2017310163A AU 2017310163 B2 AU2017310163 B2 AU 2017310163B2
Authority
AU
Australia
Prior art keywords
region
cells
heterodimeric
cancer
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017310163A
Other languages
English (en)
Other versions
AU2017310163A1 (en
Inventor
Dong Ki Choi
Hye Ji Choi
Ji Hee Ha
Keunok JUNG
Ye Jin Kim
Yong Sung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajou University Industry Academic Cooperation Foundation filed Critical Ajou University Industry Academic Cooperation Foundation
Priority claimed from PCT/KR2017/008676 external-priority patent/WO2018030806A1/ko
Publication of AU2017310163A1 publication Critical patent/AU2017310163A1/en
Application granted granted Critical
Publication of AU2017310163B2 publication Critical patent/AU2017310163B2/en
Priority to AU2021273642A priority Critical patent/AU2021273642B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017310163A 2016-08-10 2017-08-10 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same Active AU2017310163B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021273642A AU2021273642B2 (en) 2016-08-10 2021-11-26 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2016-0101823 2016-08-10
KR20160101823 2016-08-10
KR1020170101594A KR102050463B1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
PCT/KR2017/008676 WO2018030806A1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
KR10-2017-0101594 2017-08-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021273642A Division AU2021273642B2 (en) 2016-08-10 2021-11-26 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
AU2017310163A1 AU2017310163A1 (en) 2019-03-21
AU2017310163B2 true AU2017310163B2 (en) 2021-09-09

Family

ID=61524969

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017310163A Active AU2017310163B2 (en) 2016-08-10 2017-08-10 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
AU2021273642A Active AU2021273642B2 (en) 2016-08-10 2021-11-26 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021273642A Active AU2021273642B2 (en) 2016-08-10 2021-11-26 Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Country Status (14)

Country Link
US (4) US10696722B2 (cg-RX-API-DMAC7.html)
EP (2) EP3511340B1 (cg-RX-API-DMAC7.html)
JP (3) JP6993403B2 (cg-RX-API-DMAC7.html)
KR (4) KR102050463B1 (cg-RX-API-DMAC7.html)
CN (1) CN110267977A (cg-RX-API-DMAC7.html)
AU (2) AU2017310163B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019002394B1 (cg-RX-API-DMAC7.html)
CA (1) CA3033475A1 (cg-RX-API-DMAC7.html)
DK (1) DK3511340T3 (cg-RX-API-DMAC7.html)
ES (1) ES3000558T3 (cg-RX-API-DMAC7.html)
IL (1) IL264692B2 (cg-RX-API-DMAC7.html)
MX (2) MX386014B (cg-RX-API-DMAC7.html)
SG (1) SG11201901071TA (cg-RX-API-DMAC7.html)
ZA (1) ZA201900772B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
AU2018298060B2 (en) 2017-07-03 2021-02-25 Torque Therapeutics, Inc. Immunostimulatory fusion molecules and uses thereof
EP3753631B1 (en) 2018-02-14 2024-10-16 Lg Chem, Ltd. Catalyst loading method and method for preparation of butadiene by using same
CN110396133B (zh) * 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
JP7612571B2 (ja) * 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
AU2020358979A1 (en) * 2019-10-03 2022-04-21 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
AU2021260960A1 (en) * 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
EP4259194A4 (en) * 2020-12-10 2025-03-19 Invenra Inc. Orthogonal mutations for heterodimerization
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
AU2023378481A1 (en) * 2022-11-10 2025-06-19 Kanglitai Biomedical (Qingdao) Co., Ltd. Site-specific pegylated heteromeric protein or polypeptide, and preparation method therefor and use thereof
WO2024249320A1 (en) * 2023-05-26 2024-12-05 University Of Florida Research Foundation, Incorporated In vivo optimization of biologics
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015089A1 (en) * 1997-12-08 2010-01-21 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2014084607A1 (ko) * 2012-11-27 2014-06-05 아주대학교산학협력단 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
WO2002024223A2 (en) 2000-09-21 2002-03-28 The Brigham And Women's Hospital, Inc. Prevention and treatment of streptococcal and staphylococcal infection
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
JP4730304B2 (ja) 2004-05-20 2011-07-20 和光純薬工業株式会社 ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
US8044022B2 (en) 2005-06-08 2011-10-25 Tadeusz Kolodka Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
WO2008018519A1 (fr) 2006-08-08 2008-02-14 Seikagaku Corporation Procédé de détermination du poids moléculaire d'un acide hyaluronique
WO2008089448A2 (en) 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CA2720368C (en) 2008-04-02 2017-08-22 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
EP2270145B1 (en) 2008-04-15 2013-01-16 Wako Pure Chemical Industries, Ltd. Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
US20120034212A1 (en) 2009-01-29 2012-02-09 Michael Bowen Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases
PE20120550A1 (es) 2009-04-07 2012-05-21 Roche Glycart Ag ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET
KR20120053042A (ko) 2009-08-17 2012-05-24 로슈 글리카트 아게 표적화된 면역접합체
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
TR201815863T4 (tr) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
HUE040326T2 (hu) 2011-02-10 2019-03-28 Roche Glycart Ag Mutáns interleukon-2 polipeptidek
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PT2714718T (pt) 2011-05-24 2017-04-19 Symic Ip Llc Preparação e métodos de utilização de peptidoglicanas sintéticas que se ligam a ácido hialurónico
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013053775A1 (en) 2011-10-11 2013-04-18 Universität Zürich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US9795686B2 (en) 2012-01-19 2017-10-24 The Johns Hopkins University Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
WO2013163766A1 (en) 2012-05-04 2013-11-07 Cangene Corporation ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
EP2880169B1 (en) 2012-08-02 2017-05-17 F. Hoffmann-La Roche AG Method for producing monomeric and multimeric molecules and uses thereof
PL2880170T3 (pl) 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
HUE039291T2 (hu) 2013-03-15 2018-12-28 Hoffmann La Roche IL-22 polipeptidek és IL-22 FC fúziós fehérjék és alkalmazási eljárások
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2015171822A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
KR101721295B1 (ko) 2014-06-11 2017-04-10 주식회사 엘지화학 염화비닐계 수지의 제조방법
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
HRP20191766T1 (hr) 2014-11-06 2019-12-27 F. Hoffmann - La Roche Ag Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
ES2881771T3 (es) 2015-08-07 2021-11-30 Alx Oncology Inc Constructos que tienen un dominio de SIRP-alfa o variante del mismo
RU2770001C2 (ru) 2015-10-06 2022-04-14 Риджентс Оф Дзе Юниверсити Оф Миннесота Терапевтические соединения и способы
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
WO2018030806A1 (ko) 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
MA46534A (fr) 2016-10-14 2019-08-21 Xencor Inc Protéines de fusion fc hétérodimères il15/il15r
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
KR102286411B1 (ko) 2017-05-11 2021-08-05 이엠디 밀리포어 코포레이션 연속 유동 시스템에서 좁은 체류 시간 분포를 유지하기 위한 방법
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3066893A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
JP2019014449A (ja) 2017-07-10 2019-01-31 トヨタ自動車株式会社 車両用動力伝達装置
US20200277383A1 (en) 2017-09-07 2020-09-03 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202001772SA (en) 2017-09-21 2020-04-29 Merck Patent Gmbh Fusion protein comprising an fgf-18 moiety
KR102839644B1 (ko) 2017-09-22 2025-07-31 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 폴리펩티드 복합체
JP7450535B2 (ja) 2017-10-20 2024-03-15 エフ． ホフマン－ラ ロシュ アーゲー 単一特異性抗体から多重特異性抗体を生成させるための方法
WO2020014486A1 (en) 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015089A1 (en) * 1997-12-08 2010-01-21 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2014084607A1 (ko) * 2012-11-27 2014-06-05 아주대학교산학협력단 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILLIES S ET AL, "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases", THE JOURNAL OF IMMUNOLOGY, 1998, vol. 160, no. 12, pages 6195 - 6203 *
J. H. DAVIS ET AL, PROTEIN ENGINEERING DESIGN AND SELECTION, 2010, vol. 23, no. 4, pages 195 - 202 *
Kannan Gunasekaran ET AL, JBC Papers in Press, doi:10.1074/jbc.M110.117382, (2010-04-16), pages 1 - 20, *

Also Published As

Publication number Publication date
MX386014B (es) 2025-03-18
AU2021273642B2 (en) 2025-03-13
US11692019B2 (en) 2023-07-04
ZA201900772B (en) 2023-07-26
IL264692B1 (en) 2025-08-01
US12358964B2 (en) 2025-07-15
US20190169252A1 (en) 2019-06-06
KR20190134564A (ko) 2019-12-04
SG11201901071TA (en) 2019-03-28
KR102416411B1 (ko) 2022-07-05
IL264692A (cg-RX-API-DMAC7.html) 2019-04-30
EP3511340A1 (en) 2019-07-17
KR20230163339A (ko) 2023-11-30
BR112019002394B1 (pt) 2021-12-21
JP7111855B2 (ja) 2022-08-02
JP6993403B2 (ja) 2022-03-03
US11078249B2 (en) 2021-08-03
US20230416325A1 (en) 2023-12-28
KR102652247B1 (ko) 2024-03-29
EP4470552A2 (en) 2024-12-04
KR20220098108A (ko) 2022-07-11
KR102607285B1 (ko) 2023-12-01
JP2019536734A (ja) 2019-12-19
KR20180018419A (ko) 2018-02-21
AU2017310163A1 (en) 2019-03-21
BR112019002394A2 (pt) 2019-06-04
JP2021088601A (ja) 2021-06-10
US20200362004A1 (en) 2020-11-19
MX2019001651A (es) 2019-09-04
KR102050463B1 (ko) 2019-11-29
EP3511340A4 (en) 2020-03-18
JP7488854B2 (ja) 2024-05-22
US10696722B2 (en) 2020-06-30
CA3033475A1 (en) 2018-02-15
EP4470552A3 (en) 2025-03-05
IL264692B2 (en) 2025-12-01
ES3000558T3 (en) 2025-02-28
US20200362005A1 (en) 2020-11-19
AU2021273642A1 (en) 2021-12-16
JP2022137288A (ja) 2022-09-21
DK3511340T3 (da) 2025-01-02
CN110267977A (zh) 2019-09-20
MX2021010809A (es) 2021-10-01
EP3511340B1 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
AU2021273642B2 (en) Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US12421292B2 (en) Anti-DLL3 chimeric antigen receptors and uses thereof
US20200399336A1 (en) Il-21 (heterodimeric fc-fused il-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric fc), and pharmaceutical composition comprising same
US12319725B2 (en) IL-2 mutant and application thereof
JP2020536552A (ja) Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用
JP2020536552A5 (cg-RX-API-DMAC7.html)
JP2022532249A (ja) インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法
US20250333507A1 (en) Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereof
KR20250160456A (ko) Tnf 슈퍼패밀리 멤버 면역사이토카인 및 이의 용도
JP2022526194A (ja) Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
HK40014568A (en) Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same
TW202426503A (zh) 癌症治療中與ｐｄ－１訊息抑制劑組合之抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體的用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HETERODIMERIC FC-FUSED CYTOKINE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

FGA Letters patent sealed or granted (standard patent)